Literature DB >> 2265496

Preparation of anti-T idiotype monoclonal antibody reacting with human T leukaemic cell lines and with a small percentage of peripheral T lymphocytes.

T Takahashi1, K Imai, T Sugiyama, T Sasaki, A Yachi.   

Abstract

Monoclonal antibody (MoAb) KT38 raised against a human T leukaemic cell line TALL-1, reacted with another T leukaemic cell line Jurkat, but not with any other cell lines tested. The co-modulation of CD3 and KT38 antigen was observed with stimulations of either MoAb T3 or KT38 on both TALL-1 and Jurkat. Upon radioimmunoprecipitation and SDS-PAGE analysis, MoAb KT38 precipitated the heterodimer of 40-60 kD from Jurkat and TALL-1 under reducing conditions. Thus, MoAb KT38 is considered to be an anti-T idiotype (Ti) antibody to TALL-1 and Jurkat cells. MoAb KT38 was also shown to react with a minor population of peripheral blood lymphocytes (PBL) and with very few cells (0.5-2.0%) in the paracortical area of the lymph node. When PBL were stimulated in a KT38-coated culture flask for 5 days, the percentage of KT38-positive PBL was markedly increased. The CD3 antigen on these cultured PBL in the flask was modulated by the stimulation with MoAb KT38. Thus, it is suggested that a common idiotope exists on the T cell receptor of Jurkat, TALL-1 and a small percentage (1.9-6.1%) of PBL.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2265496      PMCID: PMC1535498          DOI: 10.1111/j.1365-2249.1990.tb05495.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  21 in total

1.  The reliability of molecular weight determinations by dodecyl sulfate-polyacrylamide gel electrophoresis.

Authors:  K Weber; M Osborn
Journal:  J Biol Chem       Date:  1969-08-25       Impact factor: 5.157

2.  Cross-linking of human T cell receptor proteins: association between the T cell idiotype beta subunit and the T3 glycoprotein heavy subunit.

Authors:  M B Brenner; I S Trowbridge; J L Strominger
Journal:  Cell       Date:  1985-01       Impact factor: 41.582

3.  The role of T3 surface molecules in the activation of human T cells: a two-stimulus requirement for IL 2 production reflects events occurring at a pre-translational level.

Authors:  A Weiss; R L Wiskocil; J D Stobo
Journal:  J Immunol       Date:  1984-07       Impact factor: 5.422

4.  A new generation of Ca2+ indicators with greatly improved fluorescence properties.

Authors:  G Grynkiewicz; M Poenie; R Y Tsien
Journal:  J Biol Chem       Date:  1985-03-25       Impact factor: 5.157

5.  The major histocompatibility complex-restricted antigen receptor on T cells in mouse and man: identification of constant and variable peptides.

Authors:  J Kappler; R Kubo; K Haskins; C Hannum; P Marrack; M Pigeon; B McIntyre; J Allison; I Trowbridge
Journal:  Cell       Date:  1983-11       Impact factor: 41.582

6.  Growth of normal human T lymphocytes induced by monoclonal antibody to the T cell antigen receptor.

Authors:  A W Boylston; P Cosford
Journal:  Eur J Immunol       Date:  1985-07       Impact factor: 5.532

7.  Detection of novel proteins associated with secondary amyloidosis and Alzheimer's disease by monoclonal antibody.

Authors:  T Yamashita; K Imai; N Saito; A Yachi
Journal:  Brain Res       Date:  1988-12-06       Impact factor: 3.252

8.  A clinical trial of anti-idiotype therapy for B cell malignancy.

Authors:  T C Meeker; J Lowder; D G Maloney; R A Miller; K Thielemans; R Warnke; R Levy
Journal:  Blood       Date:  1985-06       Impact factor: 22.113

9.  Antigen-like effects of monoclonal antibodies directed at receptors on human T cell clones.

Authors:  S C Meuer; J C Hodgdon; R E Hussey; J P Protentis; S F Schlossman; E L Reinherz
Journal:  J Exp Med       Date:  1983-09-01       Impact factor: 14.307

10.  Clonotypic structures involved in antigen-specific human T cell function. Relationship to the T3 molecular complex.

Authors:  S C Meuer; K A Fitzgerald; R E Hussey; J C Hodgdon; S F Schlossman; E L Reinherz
Journal:  J Exp Med       Date:  1983-02-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.